M&A

News

Hippocratic AI has expanded with the acquisition of Grove AI, a specialist in AI used in pharma R&D, building on its patient-facing GenAI agents.

News

Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.

News

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

News

Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

R&D

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.